Core Viewpoint - The company, Huaren Health, has shown a positive financial performance with significant growth in revenue and net profit, despite a relatively high PE ratio compared to the industry average [1][2]. Group 1: Financial Performance - For the fiscal year 2024, the company achieved a record revenue of 4.532 billion yuan, representing a year-on-year growth of 19.34% [1]. - The net profit attributable to the parent company was 138 million yuan, an increase of 20.09% compared to the previous year [1]. - The net profit after deducting non-recurring gains and losses was 129 million yuan, reflecting a growth of 21.81% year-on-year [1]. - In the latest quarterly report for Q1 2025, the company reported a revenue of 1.267 billion yuan, which is a year-on-year increase of 14.71% [2]. - The net profit for Q1 2025 was 61.22 million yuan, showing a year-on-year growth of 28.15% [2]. - The operating cash flow has shown continuous improvement, indicating a steady enhancement in operational quality [1]. Group 2: Market Position and Valuation - As of July 23, the company's stock closed at 14.8 yuan, with a PE ratio of 39.17, marking a new low in 17 days [1]. - The total market capitalization of Huaren Health is 5.92 billion yuan [1]. - In comparison to the pharmaceutical retail industry, the average PE ratio is 42.87, while the median is 29.04, placing Huaren Health at the 22nd position within the industry [1]. - The company has two institutional investors holding a total of 7700 shares, with a market value of 0.00 billion yuan [1].
华人健康收盘上涨2.78%，滚动市盈率39.17倍，总市值59.20亿元